Oncolytics initiates randomized colorectal cancer study

Oncolytics (ONCY) Biotech announced the initiation of a metastatic colorectal cancer, mCRC, Phase 2 study that will be referred to as REO 033. In this trial, second-line RAS-mutated, microsatellite-stable mCRC patients will be randomized to a control arm of bevacizumab and fluorouracil, leucovorin, irinotecan or an experimental arm of pelareorep, bevacizumab, and FOLFIRI. The study is powered for statistical significance, with each study arm expected to enroll 30 patients. All participants will have failed their initial treatment with platinum-based chemotherapy. The primary endpoint of the study is objective response rate, with progression-free survival, overall survival , safety, and biomarker analysis as other endpoints.